No images? Click here
Hello ,
Welcome to The Sugar Source, a monthly newsletter on recent updates in T1D research from The Sugar Science! Below you will find select papers, preprints, and business updates related to T1D from December.
Papers of the Month
hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair
December 13, 2022
Functional and Taxonomic Traits of the Gut Microbiota in Type 1 Diabetes Children at the Onset: A Metaproteomic Study
December 15, 2022
Fas Ligand-Modified Scaffolds Protect Stem Cell Derived β-Cells by Modulating Immune Cell Numbers and Polarization
December 19, 2022
Gut microbiota composition is altered in a preclinical model of type 1 diabetes mellitus: Influence on gut steroids, permeability, and cognitive abilities
December 23, 2022
miRNA Theranostic Nanoparticles Promote Pancreatic Beta Cell Proliferation in Type 1 Diabetes Model
December 13, 2022
A porcine islet-encapsulation device that enables long-term discordant xenotransplantation in immunocompetent diabetic mice
December 19, 2022
Pancreatic Pathological Changes in Murine Toxoplasmosis and Possible Association with Diabetes Mellitus
December 22, 2022
Preprints of the Month
The type 1 diabetes-associated lncRNA ARGI participates in virus-induced pancreatic β cell inflammation
December 2, 2022
Polyacrylamide-based Hydrogel Coatings Improve Biocompatibility of Implanted Pump Devices
December 14, 2022
Delineating mouse β-cell identity during lifetime and in diabetes with a single cell atlas
December 22, 2022
Business Updates
Dexcom has received approval for from the FDA for their G7 continuous glucose monitor device in diabetes patients 2 and up. The G7 is smaller and more accurate than the G6 predecessor.
Eli Lilly has left their partnership with Ypsomed for an automated insulin pump. Ypsomed will continue to submit their YpsoPump to the FDA, but Eli Lilly plans to focus their resources on its own connected pen platform.
Embecta, which spun off of BD earlier this year, has outperformed their revenue estimates with full-year revenues of nearly $1.13B and $566M in their first 6 months. While the 1.13B was 3% decrease compared to the previous year, the previous year's revenue was from when Embecta was still under BD, making comparison less meaningful.
Lexicon is still trying to get an audience with the FDA to try and get their T1D drug candidate, sotagliflozin, approved. The FDA rejected the drug in 2019 on the grounds that sotagliflozin and insulin treatment increased the risk of diabetic ketoacidosis.
Tandem is entering an acquisition deal with AMF Medical based in Switzerland. AMF is currently developing a patch pump to automatically deliver insulin. The deal value totals to $216M, and doubles Tandem's diabetes tech lineup.
Terasaki Innovation Summit
March 8 - 10, 2023
The Terasaki Institute for Biomedical Innovation (TIBI) will be hosting the Terasaki Innovation Summit on March 8-10, 2023, at the UCLA Meyer & Renee Luskin Center in Los Angeles. This inaugural event will focus on improving technological and entrepreneurial translation of personalized medicines. The Inaugural Terasaki Innovation Summit will include leading investigators discussing the latest advances in micro- and nanotechnologies and applications in diagnostics, therapeutic drug delivery and regenerative medicine. Early bird registration ends December 16, 2022.
2023 Clinical Update Conference
February 10-12, 2023
The Clinical Update Conference offers a first in-depth discussion at what's new in the ADA's Standards of Care in Diabetes—2023. All sessions will include practical clinical guidance on the latest evidence and newest clinical practice recommendations. This conference is designed for all health care professionals who provide clinical care and education for people with diabetes. Physicians, advanced practice providers (physician associates and nurse practitioners), nurses, dietitians, pharmacists, certified diabetes care and education specialists, mental health professionals, and others will benefit from this continuing education conference. Leading-edge information will be provided in a case-based format in this interactive learning environment.
